At the Thoracic Oncology Group of Australasia (TOGA), we understand that the fight against thoracic cancers requires continuous innovation and a commitment to advancing patient care. Clinical trials are the bedrock of this progress, driving the development of new and more effective treatments that can significantly improve the lives of individuals facing these challenging diagnoses.
The power of clinical trials: Transforming lives
Clinical trials are research studies that explore whether new medical strategies, treatments, or devices are safe and effective for people. They are essential for:
- Discovering New Treatments: Clinical trials have been instrumental in identifying groundbreaking treatments that extend survival, manage symptoms, and enhance quality of life. For patients with thoracic cancers, these advancements can mean more time with loved ones and a better overall experience.
- Personalising Treatment Approaches: The results obtained from clinical trials enable researchers to pinpoint factors that influence treatment effectiveness in different individuals. This allows for more personalised and targeted therapies, maximiaing the potential benefits for each patient.
- Ensuring Safety and Efficacy: The Australian Government mandates clinical trials to provide evidence that a new medicine or treatment is both safe and effective before it can be made widely available. This rigorous process safeguards patient well-being and ensures that new therapies meet the highest standards.
TOGA’s commitment to advancing thoracic oncology through clinical trials
TOGA is committed to conducting and supporting quality clinical trials that address the unmet needs of patients with thoracic cancers. We are proud to be involved in a range of trials investigating innovative treatments and strategies. Here are some of our current and recent clinical trials:
- ADOPT-Lung: A clinical trial is designed to determine if early-stage NSCLC patients who receive chemotherapy and immunotherapy prior to surgery have longer disease-free survival if they are also treated with immunotherapy after surgery.
- ASPiRATION: A cohort study to assess the clinical impact of comprehensive genomic profiling in metastatic lung cancer patients
- DYNAMALK: A trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ NSCLC
- SHERLOCK: A trial is exploring the effectiveness of Sotorasib, an oral medication, in combination with Carboplatin, Pemetrexed, and Bevacizumab.
- OCEANiC: A phase II multi-centre clinical trial targeting patients with resected stage II to IIIA EGFR mutant NSCLC.
Why participate in a clinical trial?
Participating in a clinical trial offers several potential benefits:
- Access to cutting-edge treatments that may not be available elsewhere.
- Close monitoring and care from a team of experienced healthcare professionals.
- The opportunity to contribute to the advancement of medical knowledge and improve outcomes for future patients.
TOGA’s role in thoracic oncology research
TOGA plays a crucial role in facilitating and supporting clinical trials across Australasia. We bring together leading researchers, clinicians, and patient advocates to drive innovation and improve the lives of individuals affected by thoracic cancers. Our collaborative approach ensures that research findings are translated into clinical practice, bringing the latest advancements to patients as quickly as possible.
Getting involved in clinical trials
If you or someone you know is facing a thoracic cancer diagnosis, we encourage you to discuss clinical trial options with your healthcare provider. Together, we can work towards a future where thoracic cancers are effectively treated and prevented.
Important considerations:
- Always consult with your physician before making any decisions about participating in a clinical trial.
- Ensure you understand the risks and benefits associated with any clinical trial.
- It is very important to include links to the clinical trials on your website, or to the australian clinical trials registry.
